Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 601–700 of 1,001
Marques, P., Barry, S., Ronaldson, A., Ogilvie, A., Storr, H. L., Goadsby, P. J., Powell, M. P., Dang, M. N., Chahal, H., Evanson, J., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8581626 · Cited by 15
“Hyperprolactinaemia is common, due to physiological changes (stress, food ingestion, exercise, coitus, chest stimulation, sleep, lactation, and pregnancy), diseases (epilepsy, renal failure, cirrhosis, chest trauma, hypothyroidism, and polycystic ovary syndrome), or medications [56].”
BackgroundMaldaner, N., Serra, C., Tschopp, O., Schmid, C., Bozinov, O., & Regli, L. (2018) · Praxis · doi:10.1024/1661-8157/a003035 · Cited by 13
Etiological profile of galactorrhoea
Sarathi, V., Atluri, S., Amit, G., Boppana, R., & Shivaprasad, C. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_89_18 · Cited by 13
“antihypertensives, opioids that act by blocking D2 receptors or decrease synthesis of dopamine can reduce the hypothalamic inhibitory tone on pituitary and thereby can increase in prolactin secretion which may cause galactorrhea.[3,4] Usually the prolactin elevation due to drugs is <100 ng/ml except for few antipsycho…”
BackgroundMethodInfluentialTuleasca, C., Ducos, Y., Leroy, H., Chanson, P., Knafo, S., Levivier, M., Aghakhani, N., & Parker, F. (2020) · Acta Neurochirurgica · doi:10.1007/s00701-020-04300-1 · Cited by 14
Majumdar, A., & Mangal, N. (2015) · Springer eBooks · doi:10.1007/978-81-322-1686-5_29 · Cited by 13
Almazrouei, R. A., Zaman, S., Wernig, F., & Meeran, K. M. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211025276 · Cited by 12
Chen, A., Cao, C., Liu, B.-X., Wang, S., Wu, S., Xu, G., & Song, J. (2022) · Brain Sciences · doi:10.3390/brainsci12081091 · Cited by 12
“Prolactinoma is the most common subtype of PAs (accounting for up to 60%), of which the main clinical damages are attributed to tumor local mass effects and prolactin oversecretion [21].”
Backgroundvan Trigt, V. R., Bakker, L. E. H., Pelsma, I. C. M., Zandbergen, I. M., Jentus, M. M., Kruit, M. C., Dekkers, O. M., van Furth, W. R., Verstegen, M. J. T., Biermasz, N. R., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae652 · Cited by 12
Mathioudakis, N. N., Sundaresh, R., Giantini-Larsen, A., Ruff, W. E., Schiller, J., Guerrero‐Cazares, H., Burger, P. C., Salvatori, R., & Quiñones‐Hinojosa, A. (2014) · Pituitary · doi:10.1007/s11102-014-0553-1 · Cited by 12
Antipsychotic-induced hyperprolactinaemia: case studies and review
Mittal, S., Prasad, S., & Ghosh, A. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135221 · Cited by 12
MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment
Aydın, B., Arslan, S., Bayraklı, F., Karademir-Yilmaz, B., & Arğa, K. Y. (2021) · Neuroendocrinology · doi:10.1159/000515801 · Cited by 14
Cander, S., Gül, Ö. Ö., Eylemer, E., Boz, E. G., Güneş, E., Hakyemez, B., Yılmazlar, S., & Ersoy, C. (2021) · HORMONES · doi:10.1007/s42000-021-00307-0 · Cited by 12
Campana, C., Nista, F., Castelletti, L., Caputo, M., Lavezzi, E., Marzullo, P., Ferrero, A., Gaggero, G., Canevari, F. R., Rossi, D. C., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01758-x · Cited by 12
“This scenario is clearly different from the management of “classical” pituitary prolactinomas, which are treated with first-line medical therapy in the vast majority of cases [138, 139], while surgery is reserved only for selected cases [140].”
BackgroundKim, S.-I., Yoon, J. H., Park, D. C., Yang, S., & Kim, Y. I. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.80891 · Cited by 18
“Prolactinoma is the most common cause of HPRL other than physiological conditions such as pregnancy and lactation, which account for 40% of all pituitary tumors [9].”
BackgroundInfluentialSurgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality
Kim, E. H., Kim, J., Ku, C. R., Lee, E. J., & Kim, S. H. (2023) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0406 · Cited by 12
“Key Words: Dopamine agonist, pituitary adenoma, prolactinoma, transsphenoidal surgery Original Article pISSN: 0513-5796 · eISSN: 1976-2437 Received: September 7, 2022 Revised: May 1, 2023 Accepted: June 1, 2023 Published online: July 18, 2023 Corresponding author: Sun Ho Kim, MD, PhD, Department of Neurosurgery, Yonse…”
MethodInfluentialReproduction and energy balance: the integrative role of prolactin
Romantsova, T. I. (2014) · Obesity and metabolism · doi:10.14341/omet201415-18 · Cited by 14
Jiang, X.-B., Hu, B., He, D., Mao, Z.-G., Wang, X., Song, B., Zhu, Y., & Wang, H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1595-0 · Cited by 12
“Prolactinomas are among the most prevalent secretory pituitary adenomas and are usually controlled by dopamine agonists, with or without adjuvant surgical and radiation therapy [1].”
BackgroundClinical Management of Antipsychotic-Induced Hyperprolactinemia
Wong‐Anuchit, C. (2015) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12111 · Cited by 14
“Because the circadian rhythm, mealtime, and increased stress can cause an elevation of the prolactin level, obtaining the sample in the very early morning, or less than an hour after a copious meal with excessive venipuncture stress, should be avoided to ensure the accuracy of the results (Melmed et al., 2011).”
BackgroundInfluentialProlactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy
Kim, D., Ku, C. R., Kim, K., Jung, H., & Lee, E. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0753 · Cited by 12
Rak, B., Maksymowicz, M., Grzywa, T. M., Sajjad, E. A., Pękul, M., Wlodarski, P. K., & Zieliński, G. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0011 · Cited by 12
Ectopic Prolactin Secretion From a Uterine Leiomyoma
Sachdev, S., Reyes, M. C., & Snyder, P. J. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa035 · Cited by 12
De-implementing low-value care in endocrinology
Ospina, N. S., Salloum, R. G., Maraka, S., & Brito, J. P. (2021) · Endocrine · doi:10.1007/s12020-021-02732-y · Cited by 14
Mills, E., & Dhillo, W. S. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13201 · Cited by 13
“Dopamine agonists are highly effective in most cases by normalising prolactin levels and restoring eugonadism.(65) However, resistance occurs with bromocriptine and cabergoline in approximately 20%–30% and 10% of patients, respectively,(66) underscoring the need for alternative therapies for resistant and intolerant p…”
BackgroundKurosaki, M., Kambe, A., Ishibashi, M., Watanabe, T., & Horie, Y. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0175-3 · Cited by 12
Prolactin in Human Reproduction
Molitch, M. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00003-2 · Cited by 15
The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors
Jaursch-Hancke, C., Deutschbein, T., Knappe, U. J., Saeger, W., Flitsch, J., & Faßnacht, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0015 · Cited by 16
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas
Karamouzis, I., Berardelli, R., Prencipe, N., Berton, A. M., Bona, C., Stura, G., Corsico, M., Gasco, V., Maccario, M., Ghigo, E., et al. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0361-0 · Cited by 13
“Patients were enrolled in this study based on the following criteria: (1) imaging features suggestive of pituitary adenoma [22]; (2) absence of any biochemical and clinical evidence of hormonal excess [exclusion of Cushing’s syndrome according to international criteria, including normal 24-h urinary free cortisol and/…”
MethodPathophysiology and Medical Management of Hypoactive Sexual Desire Disorder
Clayton, A. H., & Vignozzi, L. (2018) · Wiley eBooks · doi:10.1002/9781119266136.ch6 · Cited by 15
Hyperandrogenemia and high prolactin in congenital utero–vaginal aplasia patients
Oppelt, P. G., Müller, A., Stephan, L., Dittrich, R., Lermann, J. H., Büttner, C., Ekici, A. B., Conzelmann, G., Seeger, H., Schöller, D., et al. (2017) · Reproduction · doi:10.1530/rep-16-0408 · Cited by 11
“…serum levels: elevated TT ( > 2.0 nmol/L), cFT ( > 0.03 nmol/L) or cBT ( > 0.71 nmol/L) according to Mueller and coworkers (Mueller et al. 2006 a , b ); (3) MRKH with hyperprolactinemia but normal androgen serum levels: elevated PRL over 530 IU/L according to Melmed and coworkers (Melmed et al .”
BackgroundInfluentialThe Role of Hormones in Male Sexual Function
Dick, B. P., Koller, C. R., Herzog, B. J., Greenberg, J. W., & Hellstrom, W. J. G. (2020) · Current Sexual Health Reports · doi:10.1007/s11930-020-00271-7 · Cited by 24
Glezer, A., & Bronstein, M. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_5 · Cited by 11
Sanjan, G., Das, L., Ahuja, C. K., Dhandapani, S., Sachdeva, N. K., Grover, S., & Dutta, P. R. (2023) · Neurology India · doi:10.4103/0028-3886.370452 · Cited by 11
Lee, G. Y., Kim, S. H., & Kim, E. H. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2023.0023 · Cited by 11
“DA therapy failure was defined as a decrease of <50% in the tumor size after bromocriptine or cabergoline administration or the failure of normalization of prolactin level or DA cessation owing to their side effects [9,10].”
BackgroundGlezer, A., Garmes, H. M., Kasuki, L., Martins, M. R. A., Elias, P. C. L., Nogueira, V. D. S. N., Silva, A. C. J. D. S. R. E., Maciel, G. A. R., Benetti‐Pinto, C. L., & Nácul, A. P. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0502 · Cited by 11
“If venipuncture poses no challenge, a single blood sample is sufficient to determine the presence of hyperprolactinemia (5,6).”
BackgroundInfluentialBreast Cancer Risk and Management in the Endocrine Clinic: A Comprehensive Review
Hawazie, A., & Druce, M. R. (2025) · Clinical Endocrinology · doi:10.1111/cen.15209 · Cited by 12
Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup
Wu, Z. R., Zhang, Y., Cai, L., Lin, S., Su, Z. P., Wei, Y. X., Shang, H. B., Yang, W. L., Zhao, W. G., & Wu, Z. B. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8580750 · Cited by 11
Response Activation and Inhibition in Patients With Prolactinomas: An Electrophysiological Study
Song, J., Cao, C., Wang, Y., Yao, S., Catalino, M. P., Yan, D., Xu, G., & Lianting, M. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.00170 · Cited by 11
Mehla, S., Chua, A. L., Grosberg, B. M., & Evans, R. W. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13987 · Cited by 11
“pituitary stalk which also gets compressed early on when the herniation of subarachnoid space begins.(4,17)”
BackgroundSearle, L., McDowell, S., Willink, R., & Krebs, J. D. (2021) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13416 · Cited by 13
Costs and Its Determinants in Pituitary Tumour Surgery
Dekkers, A. J., de Vries, F., Najafabadi, A. H. Z., van der Hoeven, E. M., Verstegen, M. J. T., Pereira, A. M., van Furth, W. R., & Biermasz, N. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905019 · Cited by 14
Quality reporting of radiomics analysis in pituitary adenomas: promoting clinical translation
Won, S. Y., Lee, N., Park, Y. W., Ahn, S. S., Ku, C. R., Kim, E. H., & Lee, S. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220401 · Cited by 11
Xiao, L., Ouyang, T., Wu, B., Xie, S., Tang, B., He, Y., Ding, H., Wu, X., & Hong, T. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002197 · Cited by 15
“9) Follow-up time, mo 38 (8-60) 36 (10-55) 39 (8-58) 38 (9-60) Preoperative symptoms Headache 26 (20.”
Is Rational Antipsychotic Polytherapy Feasible? A Selective Review
Kroken, R. A., & Johnsen, E. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0266-y · Cited by 11
“The effect of D2-blockade in the anterior pituitary lactotroph cells by most antipsychotics is hyperprolactinemia, which can be asymptomatic or may induce hypogonadism, infertility, galactorrhea, and bone loss secondary to sex hormone attenuation [47].”
BackgroundIs receptor profiling useful for predicting pituitary therapy?
Marazuela, M., Ramos-Leví, A., de Souza, P. B., & Zatelli, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0549 · Cited by 9
Ceccato, F., Lombardi, G., Albiger, N. M. E., Mazzai, L., Pambuku, A., Rolma, G., Zagonel, V., & Scaroni, C. M. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000768 · Cited by 11
Yamaguchi, M., Erdenebaatar, C., Saito, F., Honda, R., Ohba, T., Kyo, S., Tashiro, H., & Katabuchi, H. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz029 · Cited by 12
Antipsychotics-induced hyperprolactinemia and screening for macroprolactin
Ruljančić, N., Bakliža, A., Filipčić, I., Grošić, V., Ivezić, E., Matić, K., Gereš, N., & Pisk, S. V. (2020) · Biochemia Medica · doi:10.11613/bm.2021.010707 · Cited by 13
“There is compelling evidence for the routine screening of hyperprolactinemic serum for MPRL (2).”
BackgroundAlikaşifoğlu, A., Çelik, N. B., Özön, Z. A., Gonc, E. N., & Kandemir, N. (2021) · Pituitary · doi:10.1007/s11102-021-01184-x · Cited by 11
Cao, C., Huang, Y., Chen, A., Xu, G., & Song, J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.656255 · Cited by 12
Liu, J., Wang, J., Tian, W., Xu, Y., Li, R., Zhao, K., You, C., Zhu, Y., Bartsch, J. W., Niu, H., et al. (2022) · Aging · doi:10.18632/aging.204206 · Cited by 11
Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas
Kurosaki, M., Kambe, A., Watanabe, T., Fujii, S., & Ogawa, T. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000457 · Cited by 12
Athanasoulia, A. P., Sievers, C., Uhr, M., Ising, M., Stalla, G. K., & Schneider, H. J. (2013) · Pituitary · doi:10.1007/s11102-013-0496-y · Cited by 12
Evaluation of pituitary function
Cheer, K., & Trainer, P. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00010-1 · Cited by 12
Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma
Dogan, B. A., Arduç, A., Tuna, M. M., İmga, N. N., Işık, S., Berker, D. S., & Güler, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6416 · Cited by 11
“Inclusion criteria From a group of 115 patients with prolactinoma, 42 nonobese women with microprolactinoma who met the Pituitary Society criteria (9) for the withdrawal of long-term CAB therapy participated in our study.”
BackgroundMethodResultInfluentialProlactinoma Outcome After Pregnancy and Lactation: A Cohort Study
Laway, B. A., Baba, M. S., Bansiwal, S. K., & Choh, N. A. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_372_21 · Cited by 10
Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited
Sosa, E., & Espinosa-Cárdenas, E. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102893 · Cited by 10
Ke, D., Xu, L., Wu, D., Yang, S., Liu, S., Xie, M., & Xiao, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1255768 · Cited by 10
Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
Varaldo, E., Cuboni, D., Prencipe, N., Aversa, L. S., Sibilla, M., Bioletto, F., Berton, A. M., Gasco, V., Ghigo, E., & Grottoli, S. (2024) · Endocrine · doi:10.1007/s12020-023-03678-z · Cited by 12
“Furthermore, in contrast to previous studies [13, 14], our statistical analysis excluded patients with both macroPRL, who should not undergo further diagnostic testing, as well as subjects with PRL levels indicative of a pituitary etiology ( >250 µg/L and >500 µg/L) [5, 8].”
BackgroundResultInfluentialDiffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas
Barbosa, M. Á., Pereira, E., Pereira, P. J. D. M., Guasti, A., Andreiuolo, F. D. M., Chimelli, L. M. C., Kasuki, L., Ventura, N., & Gadelha, M. R. (2024) · Pituitary · doi:10.1007/s11102-023-01377-6 · Cited by 11
Prencipe, N., Bona, C., Cuboni, D., Berton, A. M., Bioletto, F., Varaldo, E., Aversa, L. S., Sibilla, M., Gasco, V., Ghigo, E., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01384-1 · Cited by 10
“Despite the demonstration that DAs used previously and during pregnancy are safe drugs, the Endocrine Society recommends the immediate suspension of medical therapy once pregnancy is confirmed as a precaution [4].”
Zaidalkilani, A. T., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., AL-Farga, A. M., Alghamdi, O. A., Bahaa, M. M., Alrouji, M., Alshammari, M. S., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70067 · Cited by 11
Patterns of invasion of the medial wall of the cavernous sinus by pituitary adenomas
Constanzo, F., Rychen, J., Lee, C. K., Decker, J. H., Fischbein, N. J., Johnstone, T. M., Ljubimov, V. A., Vigo, V., & Fernandez-Miranda, J. C. (2025) · Journal of neurosurgery · doi:10.3171/2025.3.jns242823 · Cited by 16
Saadat, N., Esmaily, H., Abbasinazari, M., Tohidi, M., Salamzadeh, J., Hadaegh, F., Tolabi, M., Kalantar-Hormozi, M., & Dibaj, M. (2015) · PubMed Central · Cited by 11
Serial prolactin sampling as a confirmatory test for true hyperprolactinemia
Francés, C., Boix, E., Fajardo, M. T., & Gómez-García, J. M. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.11.006 · Cited by 10
“However, the Endocrine Society Guidelines for the diagnosis and treatment of hyperprolactinemia advise that a single measurement of prolactin in a blood sample obtained at any time of the day will usually be adequate to document hyperprolactinaemia, as long as the sample is withdrawn without excessive venepuncture str…”
BackgroundInfluentialUpdate on vertebral fractures in pituitary diseases: from research to clinical practice
Carrone, F., Ariano, S. A., Piccini, S., Milani, D., Mirani, M., Balzarini, L., Lania, A. G., & Mazziotti, G. (2021) · HORMONES · doi:10.1007/s42000-021-00275-5 · Cited by 11
Kim, J.-H., Hur, K.-Y., Hong, S.-D., Choi, J., Seol, H. J., Nam, D., Lee, J.-I., & Kong, D. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.12.074 · Cited by 10
Düğer, H., Bostan, H., Deryol, H. Y., İmga, N. N., Uçan, B., Çalapkulu, M., Hepşen, S., Akhanlı, P., Gül, Ü., Sencar, M. E., et al. (2022) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2022.101501 · Cited by 10
Kontbay, T., Şıklar, Z., Özsu, E., Uyanık, R., Bilici, M. E., Ceran, A., & Berberoğlu, M. (2022) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2021.4639 · Cited by 10
Zeng, Y., Huang, Q., Zou, Y., Tan, J., Zhou, W., & Li, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1027905 · Cited by 10
Findlay, M. C., Sabahi, M., Azab, M. A., Drexler, R., Rotermund, R., Ricklefs, F. L., Flitsch, J., Smith, T. R., Kilgallon, J. L., Honegger, J. B., et al. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108079 · Cited by 10
Öner, G. (2013) · InTech eBooks · doi:10.5772/55557 · Cited by 10
Iqbal, A., Novodvorský, P., Lubina-Solomon, A., Kew, F., & Webster, J. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0006 · Cited by 10
Ycaza, A. E. E. D., Chang, A. Y., Jensen, J. R., Khan, Z., & Erickson, D. Z. (2015) · Case Reports in Women s Health · doi:10.1016/j.crwh.2015.09.001 · Cited by 10
“Dopamine agonists generally are discontinued when pregnancy is confirmed [2].”
BackgroundInfluentialBarnes, R. B. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139628938.011 · Cited by 10
Bettencourt‐Silva, R., Pereira, J., Belo, S., Magalhães, D. M. D. S., Queirós, J. C., & Carvalho, D. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00312 · Cited by 11
“Transsphenoidal pituitary surgery is generally reserved for medically resistant prolactinomas or for patients who cannot tolerate high doses of these drugs (1, 11, 16).”
BackgroundInfluentialTuncer, F. N., Doğanşen, S. Ç., Serbest, E., Tanrıkulu, S., Ekici, Y., Bılgıç, B., & Yarman, S. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0133 · Cited by 11
“The results were interpreted in accordance with current recommendations and guidelines (Casanueva et al. , 2006; Nieman et al. , 2008; Katznelson et al. , 2011, 2014; Melmed et al. , 2011).”
Duan, Y., Liu, X., Hou, W., Deng, M., Gao, J. L., Zhou, C., & Xu, Y. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13957 · Cited by 13
“A clinical practice guideline published by endocrine society in 2011 suggested that clinicians should not treat asymptomatic patients harboring microprolactinomas with dopamine agonists.(20) However, this suggestion was not proposed in the context of ART, and was based on very low quality evidence.”
BackgroundResultInfluentialWitchel, S. F., & Plant, T. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00018-4 · Cited by 12
Hyperprolactinemia associated with psychiatric disorders.
Rizzo, L. F. L., Mana, D. L., Serra, H. A., & Danilowicz, K. (2020) · PubMed · Cited by 10
Kurosaki, M., Sakamoto, M., Kambe, A., & OGURA, T. (2021) · Yonago acta medica · doi:10.33160/yam.2021.05.002 · Cited by 11
Tanrıkulu, S., & Yarman, S. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1468-4608 · Cited by 10
“Domingue et al. [13] reported that normalization of pituitary MRI after pregnancy were independently associated with remission in a retrospective two-center study, which included only 19 macroadenomas.”
BackgroundInfluentialPituitary disease and pregnancy
Valassi, E. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.07.002 · Cited by 17
Zou, Y., Li, D., Gu, J., Chen, S., Xia, W., Dong, J., & Jiang, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00889-1 · Cited by 12
“DAs are effective in normalizing prolactin levels (68% of patients), reducing tumor size (62% of patients) and relieving infertility (53%) and other symptoms [4].”
BackgroundSamson, S. L., & Ezzat, S. (2014) · Endocrine Practice · doi:10.4158/ep14148.ra · Cited by 10
Prevalence of hyperprolactinemia in infertile women and its association with hypothyroidism
Nallusamy, S., & Gracelyn, L. (2015) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20151533 · Cited by 10
Llácer, J. M. B., Martínez-Hortelano, A., & Albelda, B. R. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2019.1576905 · Cited by 11
Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia
Stiles, C. E., Steeds, R. P., & Drake, W. M. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.02.007 · Cited by 10
“19 Following the MHRA’s published guidance, the Endocrine Society briefly mentioned in their 2011 hyperprolactinaemia guideline (23) that they believed that doses of 1-2mg/week of cabergoline would not require regular echocardiographic screening, though they did not grade the evidence for this.”
Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
Gonzaga, M. D. F. D. M., de Castro, L. F., Naves, L. A., Mendonça, J. L., de Lima, B. O., Kessler, I. M., & Casulari, L. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00625 · Cited by 10
Das, M., & Gogoi, C. (2023) · Scientific Reports · doi:10.1038/s41598-022-27051-8 · Cited by 14
Muro, G. D., Mangili, F., Esposito, E., Barbieri, A. M., Catalano, R., Treppiedi, D., Marra, G., Nozza, E., Lania, A. G., Ferrante, E., et al. (2023) · Cancers · doi:10.3390/cancers15123218 · Cited by 9
“DAs, especially cabergoline, are the first-choice treatment for patients with prolactin (PRL)-secreting PitNETs, since they are effective in inducing prolactin normalization and in reducing tumor size, but about 10% of patients are resistant to the treatment [1].”
BackgroundCerebrospinal Fluid Metabolomic Pattern of Different Pituitary Stalk Lesions
Wang, L., Chen, X., Liu, X., Miao, H., Gong, F., Yang, H., Duan, L., Zhu, H., & Sun, W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad559 · Cited by 9
Yang, Y., Ke, X., Duan, L., Yang, H., Gong, F., Pan, H., Wang, L., & Zhu, H. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad769 · Cited by 9
When IGF-1 Meets Metabolic Inflammation and Polycystic Ovary Syndrome
Li, X., Lin, S., Yang, X., Chen, C., Cao, S., Zhang, Q., Ma, J., Zhu, G., Zhang, Q., Fang, Q., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112529 · Cited by 10
Drug induced hypoprolactinemia
Ioachimescu, A. G., & Keleştimur, F. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09909-6 · Cited by 10
Modern approach to bone comorbidity in prolactinoma
Uygur, M. M., Menotti, S., Santoro, S., & Giustina, A. (2024) · Pituitary · doi:10.1007/s11102-024-01469-x · Cited by 10
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism
Gatto, F., Arecco, A., Amarù, J., Arvigo, M., Campana, C., Milioto, A., Espósito, D., Johannsson, G., Cocchiara, F., Maggi, D. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020465 · Cited by 13
“Bromocriptine and cabergoline (both ergot derivatives [80,81]), as well as quinagolide (a non-ergot derivative), act on binding with a preferential affinity to the dopamine receptor subtype 2 (D2DR), which is widely expressed, among others, on lac-totroph and somatotroph cells [82].”
Oberman, D. Z., Sanchez-Garavito, E. J., Perez‐Vega, C., Donaldson, A. M., Olomu, O. U., Graepel, S. P., Edgar, M. A., Quiñones‐Hinojosa, A., Chaichana, K. L., Samson, S. L., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01476-y · Cited by 14
“For prolactinomas, the criteria were: (1) normal post-operative serum prolactin levels, (2) no adenoma residual visible on post-operative imaging, and (3) no need for dopamine agonist therapy post-operatively [28].”
Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell
Su, Z., Cai, L., Lu, J., Li, C., Gui, S., Liu, C., Wang, C., Li, Q., Zhuge, Q., & Zhang, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0390-1 · Cited by 10
“Since the mid–1980s, dopamine agonists (DA) have become the first-line therapy for the patients with prolactinomas [2, 4, 5].”
BackgroundGamble, D. T., Fairley, R., Harvey, R., Farman, C., Cantley, N. W. P., & Leslie, S. J. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617703647 · Cited by 9
van der Meulen, M., Najafabadi, A. H. Z., Lobatto, D. J., van den Hout, W. B., Andela, C. D., Zandbergen, I. M., Pereira, A. M., van Furth, W. R., Vlieland, T. P. M. V., & Biermasz, N. R. (2020) · Pituitary · doi:10.1007/s11102-020-01089-1 · Cited by 12
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.